WHERE SMART SCIENCE GOES TO GROW
DTP@STAR offers flexible, state-of-the art incubation space and access to the resources development-stage companies need to drive and accelerate their economic success. The facility opened in 2016 and is located in Newark, Delaware on University of Delaware’s expansive 272-acre STAR Campus.
Access to critical resources – connections, funding sources, space and shared equipment necessary to grow and commercialize. technology
Availability of the region’s strong pool of scientific talent.
Supportive small business environment.
DTP@STAR is home to over twelve promising young companies representing innovation in agriculture, life sciences, advanced materials, renewable energy, sustainable chemistry, medical devices and information technology.
Scroll down to see our companies.
LOCATION
Close proximity to and collaborative opportunities with University of Delaware faculty, students and staff.
Access to major transportation routes including I-95, Amtrak, SEPTA and UD’s complimentary transportation services.
Find us at: 550 S College Ave, Newark, DE 19713
DTP@STAR Companies
Acrobiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins, which provides high quality protein reagents to the pharmaceutical research community. The company employs an application-oriented product development strategy, with a particular focus on protein labeling technology. The flagship MABSOL® biotinylated protein collection offers a new set of solution to assay development. These pre-labeled products have been successfully adapted to Biacore, AlphaLisa, MSD, among other established platforms.
Phone: (916) 282-9366
Fax: (916) 266-9364
Email:
Website: www.acrobiosystems.com
Address: 1 Innovation Way, Suite 400, Newark, Delaware, 19711
Foresee Pharmaceuticals
Foresee Pharmaceuticals Co., Ltd. (FP) is a clinical-stage pharmaceutical company. Our mission is to serve patients. We strive to improve patients’ quality of life and provide cure through innovative research. Foresee’s core competency includes rapid development and commercialization of new drugs using its proprietary drug delivery technology as well as develop first-in-class NCE in disease areas of high unmet medical needs. FP has two core technologies: Drug Delivery Technology： stabilized injectable formulation (SIF), a sustained-release drug delivery platform, and Rational Drug Design： novel new drug (New Chemical Entity, NCE) development. FP has also established long-term partnerships to provide the resources and flexibility required to rapidly advance an asset from research to development and eventually to commercialization.
Phone: 302-366-1785
Website: www.foreseepharma.com